Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.64 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | PREP | P48147 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668285 | 1.00 | HPGD (0.64) | HPGDRECQLMEN1ALDH1A1MAPT | |
| SCHEMBL3859089 | 0.93 | HPGD (0.71) | HPGDRECQLHRH3HSD17B10PREP | |
| SCHEMBL3716717 | 0.88 | HPGD (0.80) | HPGDRECQLMEN1ALDH1A1MAPT | |
| SCHEMBL19123138 | 0.88 | HPGD (0.80) | HPGDRECQLMEN1ALDH1A1MAPT | |
| SCHEMBL3865352 | 0.86 | HPGD (0.72) | HPGDRECQLALDH1A1HSD17B10PREP | |
| SCHEMBL600317 | 0.86 | HPGD (0.54) | HPGDRECQLMEN1ALDH1A1MAPT | |
| SCHEMBL2673507 | 0.86 | HPGD (0.85) | HPGDRECQLMEN1ALDH1A1MAPT | |
| SCHEMBL2146664 | 0.86 | HPGD (0.85) | HPGDRECQLMEN1ALDH1A1MAPT | |
| SCHEMBL20521035 | 0.86 | HPGD (0.85) | HPGDRECQLMEN1ALDH1A1MAPT | |
| SCHEMBL2673511 | 0.86 | HPGD (0.85) | HPGDRECQLMEN1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1802307-B1 | PYRROLIDINE DERIVATIVES AS HISTAMINE RECEPTORS LIGANDS | GLAXO GROUP LTD (GB) | 2008-02-27 | — | — | EP | disclosed |
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | GLAXO GROUP LIMITED (GB) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045506-A1 | Pyrrolidine Derivatives as Histamine Receptors Ligands | HRH4, HRH3, HRH2 | HPGD 192/4885RECQL 3321/4885MEN1 3805/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.